Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Raji E Joseph"'
Publikováno v:
eLife, Vol 9 (2020)
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase activ
Externí odkaz:
https://doaj.org/article/a1e7c59bd7424b1ea7e5693fd82af544
Autor:
Nikita Chopra, Thomas E Wales, Raji E Joseph, Scott E Boyken, John R Engen, Robert L Jernigan, Amy H Andreotti
Publikováno v:
PLoS Computational Biology, Vol 12, Iss 3, p e1004826 (2016)
Bruton's tyrosine kinase (Btk) is a Tec family non-receptor tyrosine kinase that plays a critical role in immune signaling and is associated with the immunological disorder X-linked agammaglobulinemia (XLA). Our previous findings showed that the Tec
Externí odkaz:
https://doaj.org/article/1b2db5e585eb47b5abfe08ef3bd48e80
Publikováno v:
Journal of Structural Biology: X, Vol 6, Iss , Pp 100061- (2022)
Cell surface receptors such as the T-cell receptor (TCR) and B-cell receptor (BCR) engage with external stimuli to transmit information into the cell and initiate a cascade of signaling events that lead to gene expression that drives the immune respo
Externí odkaz:
https://doaj.org/article/8e4f51776dd241dea5c38b325a6e6f40
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Since Dr. Ogden Bruton’s 1952 paper describing the first human primary immunodeficiency disease, the peripheral membrane binding signaling protein, aptly named Bruton’s tyrosine kinase (BTK), has been the target of intense study. Dr. Bruton’s d
Externí odkaz:
https://doaj.org/article/dac1612540c9495b93691264c444ed2f
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Frontiers in Cell and Developmental Biology
Frontiers in Cell and Developmental Biology
Since Dr. Ogden Bruton’s 1952 paper describing the first human primary immunodeficiency disease, the peripheral membrane binding signaling protein, aptly named Bruton’s tyrosine kinase (BTK), has been the target of intense study. Dr. Bruton’s d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::114685049009039b775011e838538f11
https://doi.org/10.3389/fcell.2021.655489
https://doi.org/10.3389/fcell.2021.655489
Autor:
John R. Engen, Wayland Yeung, Amy H. Andreotti, Natarajan Kannan, Raji E. Joseph, Thomas E. Wales, Annie Kwon, Neha Amatya, D. Bruce Fulton
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Bruton’s tyrosine kinase (BTK) is targeted in treatment of immune cancers. As patients experience drug resistance, there is a need for alternative approaches to inhibit BTK. Other recently published findings clarify the role of the BTK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b46e9736548b9bb59758a0fad5a17c6
https://doi.org/10.1073/pnas.1907566116
https://doi.org/10.1073/pnas.1907566116
Autor:
Raji E. Joseph, Jacques Lowe, D. Bruce Fulton, John R. Engen, Thomas E. Wales, Amy H. Andreotti
Publikováno v:
J Mol Biol
Mutations in PLCγ, a substrate of the tyrosine kinase BTK, are often found in patients who develop resistance to the BTK inhibitor Ibrutinib. However, the mechanisms by which these PLCγ mutations cause Ibrutinib resistance are unclear. Under normal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9710c8ad59f2d3eb252cc31ce8c5b04
https://doi.org/10.1016/j.jmb.2021.167422
https://doi.org/10.1016/j.jmb.2021.167422
Autor:
D. Bruce Fulton, Amy H. Andreotti, Thomas E. Wales, Neha Amatya, John R. Engen, Raji E. Joseph
Publikováno v:
eLife, Vol 9 (2020)
eLife
eLife
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::875a24ef2cb24a958e44ecdc63b3a2f6
https://elifesciences.org/articles/60470
https://elifesciences.org/articles/60470
Publikováno v:
Annual Review of Immunology. 36:549-578
Signaling through the T cell antigen receptor (TCR) activates a series of tyrosine kinases. Directly associated with the TCR, the SRC family kinase LCK and the SYK family kinase ZAP-70 are essential for all downstream responses to TCR stimulation. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3bbdca137a9f64d69a502c027ab465f
https://doi.org/10.1146/annurev-immunol-042617-053344
https://doi.org/10.1146/annurev-immunol-042617-053344